Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

MT-5111

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Molecular Templates

Drug class:

HER2 inhibitor, Protein synthesis inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

omacetaxine mepesuccinate (4)

moxetumomab pasudotox (2)

recombinant (2)

Imtox19/Imtox22 (0)

oportuzumab monatox (0)

minocycline (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

omacetaxine mepesuccinate (4)

moxetumomab pasudotox (2)

recombinant (2)

Imtox19/Imtox22 (0)

oportuzumab monatox (0)

minocycline (0)

›

HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3	MT-5111 Sensitive: C3 – Early Trials MT-5111 Sensitive : C3
HER-2 expression	Breast Cancer	HER-2 expression	Breast Cancer	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D	MT-5111 Sensitive: D – Preclinical MT-5111 Sensitive : D